Dr. Wakelee on Importance of NGS Testing in NSCLC

Video

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing (NGS) testing in the treatment of patients with non—small cell lung cancer (NSCLC).

The use of NGS testing is critical in patients with advanced-stage disease—especially in those with adenocarcinoma, Wakelee says. However, there are also patients with squamous histology, especially if they are never-smokers, who can develop driver mutations. Investigators tend to think that the classic patient with an oncogenic driver is a never-smoker who is diagnosed with adenocarcinoma, but patients with a smoking history can also have driver mutations, Wakelee stresses.

In a practice where resources are available, NGS testing should be done in every patient upfront. If resources are limited, conversations need to be had with patients. If a driver mutation is missed in a patient, then a physician is essentially missing out on giving that patient therapy that is not only well tolerated, but one that could potentially prolong their survival. It is a travesty when that happens, says Wakelee; as such, to avoid this from happening, NGS testing should be the standard.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute